Home › Compare › NLSPW vs FCPT

NLSPW vs FCPT: Dividend Comparison 2026

NLSPW yields 11173.18% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NLSPW wins by $164653833954869728.00M in total portfolio value
10 years
NLSPW
NLSPW
● Live price
11173.18%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164653833954869728.00M
Annual income
$161,805,092,740,060,000,000,000.00
Full NLSPW calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — NLSPW vs FCPT

📍 NLSPW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNLSPWFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NLSPW + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NLSPW pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NLSPW
Annual income on $10K today (after 15% tax)
$949,720.67/yr
After 10yr DRIP, annual income (after tax)
$137,534,328,829,050,980,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, NLSPW beats the other by $137,534,328,829,050,980,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NLSPW + FCPT for your $10,000?

NLSPW: 50%FCPT: 50%
100% FCPT50/50100% NLSPW
Portfolio after 10yr
$82326916977434864.00M
Annual income
$80,902,546,370,030,000,000,000.00/yr
Blended yield
98.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

NLSPW
No analyst data
Altman Z
-30.8
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NLSPW buys
0
FCPT buys
0
No recent congressional trades found for NLSPW or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNLSPWFCPT
Forward yield11173.18% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$164653833954869728.00M ✓$49.1K
Annual income after 10y$161,805,092,740,060,000,000,000.00 ✓$5,775.28
Total dividends collected$164464607760728672.00M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: NLSPW vs FCPT ($10,000, DRIP)

YearNLSPW PortfolioNLSPW Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$1,128,018$1,117,318.44$11,401$700.92+$1.12M → NLSPW
2$118,997,241$117,790,261.13$13,064$864.84+$118.98M → NLSPW
3$11,740,377,185$11,613,050,136.92$15,051$1,072.48+$11740.36M → NLSPW
4$1,083,360,524,226$1,070,798,320,638.87$17,442$1,337.22+$1083360.51M → NLSPW
5$93,504,509,375,855$92,345,313,614,932.45$20,340$1,677.08+$93504509.36M → NLSPW
6$7,548,923,892,561,273$7,448,874,067,529,108.00$23,880$2,116.57+$7548923892.54M → NLSPW
7$570,107,151,245,586,050$562,029,802,680,545,500.00$28,241$2,689.36+$570107151245.56M → NLSPW
8$40,278,627,085,882,840,000$39,668,612,434,050,070,000.00$33,660$3,442.07+$40278627085882.81M → NLSPW
9$2,662,374,967,111,925,000,000$2,619,276,836,130,030,400,000.00$40,456$4,439.95+$2662374967111925.00M → NLSPW
10$164,653,833,954,869,740,000,000$161,805,092,740,060,000,000,000.00$49,063$5,775.28+$164653833954869728.00M → NLSPW

NLSPW vs FCPT: Complete Analysis 2026

NLSPW — Stock

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Full NLSPW Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this NLSPW vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NLSPW vs SCHDNLSPW vs JEPINLSPW vs ONLSPW vs KONLSPW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.